Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 3Prostatic Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell, Peripheral 1Lymphoma 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1Enteropathy-Associated T-Cell Lymphoma 1Carcinoma, Hepatocellular 1

Interventions

Peripheral Blood Stem Cell Transplantation 2Melphalan 2Etoposide 2Cytarabine 2Cyclophosphamide 2Carmustine 2tenalisib 1tazemetostat 1romidepsin 1fludarabine phosphate 1etoposide phosphate 1Whole-Body Irradiation 1Vorinostat 1Vincristine 1Transplantation 1Tacrolimus 1Prednisone 1Prednisolone 1O(6)-benzylguanine 1Mycophenolic Acid 1IMC-001 1E7777 fusion protein 1Doxorubicin 1Cord Blood Stem Cell Transplantation 1Bortezomib 14-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma, T-Cell, Peripheral × tazemetostat × Clear all
NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Dana-Farber Cancer Institute

Phase 2 Withdrawn
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡